Literature DB >> 35726375

Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system.

Katsumi Hirose1,2, Takahiro Kato1,3,4, Takaomi Harada1, Tomoaki Motoyanagi1, Hiroki Tanaka5, Akihiko Takeuchi1, Ryohei Kato1, Shinya Komori1, Yuhei Yamazaki1, Kazuhiro Arai1,3, Noriyuki Kadoya6, Mariko Sato1,2, Yoshihiro Takai1.   

Abstract

The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT.
© The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  accelerator-based boron neutron capture therapy; dosimetric quality assurance

Mesh:

Year:  2022        PMID: 35726375      PMCID: PMC9303606          DOI: 10.1093/jrr/rrac030

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.438


  58 in total

1.  Performance measurement of the scintillator with optical fiber detector for boron neutron capture therapy.

Authors:  M Komeda; H Kumada; M Ishikawa; T Nakamura; K Yamamoto; A Matsumura
Journal:  Appl Radiat Isot       Date:  2009-03-27       Impact factor: 1.513

2.  Fractionated BNCT for locally recurrent head and neck cancer: experience from a phase I/II clinical trial at Tsing Hua Open-Pool Reactor.

Authors:  Ling-Wei Wang; Yi-Wei Chen; Ching-Yin Ho; Yen-Wan Hsueh Liu; Fong-In Chou; Yuan-Hao Liu; Hong-Ming Liu; Jinn-Jer Peir; Shiang-Huei Jiang; Chi-Wei Chang; Ching-Sheng Liu; Shyh-Jen Wang; Pen-Yuan Chu; Sang-Hue Yen
Journal:  Appl Radiat Isot       Date:  2013-12-12       Impact factor: 1.513

3.  Task Group 142 report: quality assurance of medical accelerators.

Authors:  Eric E Klein; Joseph Hanley; John Bayouth; Fang-Fang Yin; William Simon; Sean Dresser; Christopher Serago; Francisco Aguirre; Lijun Ma; Bijan Arjomandy; Chihray Liu; Carlos Sandin; Todd Holmes
Journal:  Med Phys       Date:  2009-09       Impact factor: 4.071

4.  Confirmation of a realistic reactor model for BNCT dosimetry at the TRIGA Mainz.

Authors:  Markus Ziegner; Tobias Schmitz; Rustam Khan; Matthias Blaickner; Hugo Palmans; Peter Sharpe; Gabriele Hampel; Helmuth Böck
Journal:  Med Phys       Date:  2014-11       Impact factor: 4.071

5.  Evaluation of thermal neutron irradiation field using a cyclotron-based neutron source for alpha autoradiography.

Authors:  H Tanaka; Y Sakurai; M Suzuki; S Masunaga; T Mitsumoto; Y Kinashi; N Kondo; M Narabayashi; Y Nakagawa; T Watanabe; N Fujimoto; A Maruhashi; K Ono
Journal:  Appl Radiat Isot       Date:  2014-01-24       Impact factor: 1.513

6.  Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck.

Authors:  Teruhito Aihara; Norimasa Morita; Nobuhiko Kamitani; Hiroaki Kumada; Koji Ono; Junichi Hiratsuka; Tamotu Harada
Journal:  Int J Clin Oncol       Date:  2013-06-25       Impact factor: 3.402

7.  Boron neutron capture therapy for newly diagnosed glioblastoma.

Authors:  Tetsuya Yamamoto; Kei Nakai; Teruyoshi Kageji; Hiroaki Kumada; Kiyoshi Endo; Masahide Matsuda; Yasushi Shibata; Akira Matsumura
Journal:  Radiother Oncol       Date:  2009-03-11       Impact factor: 6.280

8.  Planned fractionated boron neutron capture therapy using epithermal neutrons for a patient with recurrent squamous cell carcinoma in the temporal bone: a case report.

Authors:  Shin-Ichi Haginomori; Shin-Ichi Miyatake; Takaki Inui; Michitoshi Araki; Shinji Kawabata; Atsuko Takamaki; Koutetsu Lee; Hiroshi Takenaka; Toshihiko Kuroiwa; Yasuo Uesugi; Hiroaki Kumada; Koji Ono
Journal:  Head Neck       Date:  2009-03       Impact factor: 3.147

9.  Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine.

Authors:  Heikki Joensuu; Leena Kankaanranta; Tiina Seppälä; Iiro Auterinen; Merja Kallio; Martti Kulvik; Juha Laakso; Jyrki Vähätalo; Mika Kortesniemi; Petri Kotiluoto; Tom Serén; Johanna Karila; Antti Brander; Eija Järviluoma; Päiivi Ryynänen; Anders Paetau; Inkeri Ruokonen; Heikki Minn; Mikko Tenhunen; Juha Jääskeläinen; Markus Färkkilä; Sauli Savolainen
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

10.  Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal Cancer.

Authors:  Aaro Haapaniemi; Leena Kankaanranta; Riste Saat; Hanna Koivunoro; Kauko Saarilahti; Antti Mäkitie; Timo Atula; Heikki Joensuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-10       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.